Opportunity Information: Apply for CDC RFA GH14 1411
Apply for CDC RFA GH14 1411
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Civil Society Capacity Building for Advocacy and Response to the HIV/AIDS Epidemic Among Key Populations in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on May 19, 2014 and posted on May 9, 2014.
- Applicants must submit their applications by Jun 27, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $800,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- This Limited Eligibility Justification is to support the funding of Indian registered Indigenous Local Organizations (ILOs) using Local Capacity Initiative (LCI) funding.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Civil Society Capacity Building for Advocacy and Response to the HIV/AIDS Epidemic Among Key Populations in India" (CDC RFA GH14-1411) is a PEPFAR-supported cooperative agreement issued by the U.S. Centers for Disease Control and Prevention (CDC) under the U.S. Department of Health and Human Services (HHS). It sits within CDCs broader global HIV strategy, which typically concentrates resources on a small number of high-impact program areas in each country and emphasizes measurable improvements in HIV prevention, treatment, and public health systems. The main purpose of this specific opportunity is to strengthen civil society capacity in India, particularly organizations working with or representing key populations affected by HIV, so they can better advocate for effective responses and contribute to improved service delivery and public health outcomes.
The opportunity is categorized as discretionary funding and uses a cooperative agreement mechanism, meaning CDC would likely remain actively involved in technical direction and program collaboration rather than simply issuing a grant with minimal federal engagement. The announcement projected a single award, reflecting a focused investment in one recipient capable of coordinating or implementing a substantial package of activities. While the estimated total funding amount is listed as zero in the source data (a common artifact in some archived listings), the award ceiling is stated as up to USD 800,000, indicating the maximum expected funding level for the selected applicant. There is no cost sharing or matching requirement, which can lower barriers for local organizations that may not have flexible funds to contribute.
Eligibility was limited and intentionally targeted. The justification provided indicates the award was intended to support Indian-registered Indigenous Local Organizations (ILOs) using PEPFARs Local Capacity Initiative (LCI) funding. In practice, this signals a policy priority to route resources to local entities, build sustainable in-country leadership, and strengthen the ability of Indian civil society groups to plan, manage, and advocate within the national HIV response, especially for communities that are often underserved or face stigma and legal or social barriers to care.
Programmatically, the announcement aligns with four major CDC priority areas relevant to HIV/AIDS programming. First, it emphasizes primary prevention of HIV infection. This includes expanding confidential HIV counseling and testing services, linking testing to evidence-based behavioral change interventions, and strengthening programs that reduce mother-to-child transmission. The prevention framing suggests an intent to increase early diagnosis, reduce new infections through targeted behavior and service interventions, and improve prevention outcomes for pregnant people and infants through effective prevention-of-vertical-transmission approaches.
Second, the opportunity highlights improving care and treatment for HIV/AIDS, sexually transmitted infections, and opportunistic infections. This includes better STI management and enhanced laboratory diagnostic capacity, as well as improved clinical care for opportunistic infections. It also explicitly recognizes the importance of addressing intercurrent diseases that worsen outcomes for people living with HIV, especially tuberculosis, which remains a major co-infection concern in India. The description also notes initiation of antiretroviral therapy (ART) programs, reflecting the central role of treatment scale-up both for improving health and for reducing onward transmission.
Third, CDC stresses strengthening national capacity to collect and use surveillance data and manage HIV/AIDS programs. This includes expanding HIV, STI, and TB surveillance and reinforcing laboratory systems that support surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety. The focus on surveillance and laboratory systems points to a public health approach where programs are guided by data, outbreaks and trends are detected early, and health systems can reliably track progress and quality across prevention and treatment cascades.
Fourth, the opportunity supports developing, validating, and evaluating public health programs to improve and better target interventions related to HIV, TB, and opportunistic infections. This indicates an interest in implementation-focused learning: testing what works in real-world settings, improving program designs based on evidence, and ensuring interventions reach the populations and geographies where they will have the greatest impact. For civil society capacity building, this can translate into strengthening skills in program planning, monitoring and evaluation, quality improvement, and translating evidence into advocacy and policy dialogue.
Administratively, the opportunity was posted in May 2014, with the closing date reflected as June 27, 2014 in the current listing (after an earlier original closing date of July 27, 2014), and it was archived in August 2014. The CFDA number associated with the funding is 93.067 (Global AIDS), situating it within the U.S. governments global HIV assistance portfolio. For applicants needing help accessing the full announcement at the time, CDC provided a procurement and grants office contact line. Overall, the opportunity reflects a targeted PEPFAR investment aimed at strengthening Indian civil society organizations so they can play a more effective role in advocacy and response for key populations, while simultaneously advancing core CDC goals in HIV prevention, treatment, surveillance, laboratory systems, and evidence-driven public health programming.
Frequently Asked Questions (FAQs)
What is the title and reference number of this funding opportunity?
The funding opportunity is titled "Civil Society Capacity Building for Advocacy and Response to the HIV/AIDS Epidemic Among Key Populations in India" and is identified as CDC RFA GH14-1411.
Which U.S. government agency is offering this opportunity?
This opportunity is issued by the U.S. Centers for Disease Control and Prevention (CDC) under the U.S. Department of Health and Human Services (HHS).
Is this opportunity connected to PEPFAR?
Yes. It is described as a PEPFAR-supported cooperative agreement and is intended to support activities consistent with CDCs global HIV strategy and PEPFAR priorities.
What is the primary purpose of this opportunity?
The main purpose is to strengthen civil society capacity in India, particularly organizations working with or representing key populations affected by HIV, so they can better advocate for effective responses and contribute to improved service delivery and public health outcomes.
What type of funding is this (grant vs. cooperative agreement)?
The opportunity uses a cooperative agreement mechanism and is categorized as discretionary funding. A cooperative agreement generally indicates CDC is expected to remain actively involved in technical direction and program collaboration rather than providing minimal engagement.
How many awards were anticipated?
The announcement projected a single award, indicating a focused investment in one recipient capable of coordinating or implementing a substantial package of activities.
What is the maximum funding amount (award ceiling)?
The award ceiling is stated as up to USD 800,000, which indicates the maximum expected funding level for the selected applicant.
Why does the listing show an estimated total funding amount of zero?
The estimated total funding amount is listed as zero in the source data, which is described as a common artifact in some archived listings. The award ceiling (up to USD 800,000) provides the meaningful indicator of the maximum expected funding level.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was limited and intentionally targeted to Indian-registered Indigenous Local Organizations (ILOs) using PEPFARs Local Capacity Initiative (LCI) funding, as described in the justification provided.
What does the eligibility focus suggest about the policy intent?
The eligibility focus signals a priority to route resources to local entities, build sustainable in-country leadership, and strengthen Indian civil society groups ability to plan, manage, and advocate within the national HIV response, especially for communities that may be underserved or face stigma and other barriers to care.
What populations does the opportunity emphasize?
The opportunity emphasizes key populations affected by HIV in India, with a focus on strengthening organizations working with or representing those communities.
What are the major programmatic priority areas referenced in the announcement?
The opportunity aligns with four major CDC priority areas relevant to HIV/AIDS programming: (1) primary prevention of HIV infection, (2) improving care and treatment for HIV/AIDS, STIs, and opportunistic infections, (3) strengthening national capacity to collect and use surveillance data and manage HIV/AIDS programs, and (4) developing, validating, and evaluating public health programs to improve and better target interventions related to HIV, TB, and opportunistic infections.
What does the opportunity say about HIV prevention activities?
It emphasizes primary prevention, including expanding confidential HIV counseling and testing services, linking testing to evidence-based behavioral change interventions, and strengthening efforts that reduce mother-to-child transmission.
Does the opportunity reference prevention of mother-to-child transmission?
Yes. The prevention framing includes strengthening programs that reduce mother-to-child transmission as part of prevention-of-vertical-transmission approaches.
What care and treatment areas are highlighted?
The opportunity highlights improving care and treatment for HIV/AIDS, sexually transmitted infections (STIs), and opportunistic infections, including better STI management, enhanced laboratory diagnostic capacity, and improved clinical care for opportunistic infections.
Does the opportunity address tuberculosis (TB) in relation to HIV?
Yes. It explicitly recognizes the importance of addressing intercurrent diseases that worsen outcomes for people living with HIV, especially tuberculosis, which is described as a major co-infection concern in India.
Is antiretroviral therapy (ART) mentioned?
Yes. The description notes initiation of antiretroviral therapy (ART) programs and reflects the central role of treatment scale-up for improving health outcomes and reducing onward transmission.
What does the opportunity say about surveillance and data systems?
It stresses strengthening national capacity to collect and use surveillance data and manage HIV/AIDS programs, including expanding HIV, STI, and TB surveillance and reinforcing laboratory systems that support surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety.
What role do laboratory systems play in this opportunity?
Laboratory systems are referenced as supporting surveillance, diagnosis, treatment monitoring, disease monitoring, and HIV screening for blood safety, indicating a systems-focused public health approach.
What does the opportunity mean by developing and evaluating public health programs?
It supports developing, validating, and evaluating public health programs to improve and better target interventions related to HIV, TB, and opportunistic infections. This reflects an emphasis on implementation-focused learning and evidence-driven improvements in real-world settings.
How does this connect to civil society capacity building specifically?
Within a capacity-building framing, the emphasis on evaluation and targeting suggests strengthening skills tied to program planning, monitoring and evaluation, quality improvement, and translating evidence into advocacy and policy dialogue (as described in the opportunity summary).
When was the opportunity posted?
The opportunity was posted in May 2014.
What was the closing date?
The current listing reflects a closing date of June 27, 2014, after an earlier original closing date of July 27, 2014.
When was the opportunity archived?
The opportunity was archived in August 2014.
What CFDA number is associated with this funding?
The CFDA number associated with the funding is 93.067 (Global AIDS).
How could applicants get help accessing the full announcement at the time?
CDC provided a procurement and grants office contact line for applicants needing help accessing the full announcement.
What overall goal does the opportunity reflect?
Overall, it reflects a targeted PEPFAR investment aimed at strengthening Indian civil society organizations so they can play a more effective role in advocacy and response for key populations, while advancing CDC goals in HIV prevention, treatment, surveillance, laboratory systems, and evidence-driven public health programming.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: State Based Perinatal Quality Collaboratives
Previous opportunity: 2015 Survey of Law Enforcement Personnel in Schools (SLEPS)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH14 1411
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH14 1411) also looked into and applied for these:
| Funding Opportunity |
|---|
| State Based Perinatal Quality Collaboratives Apply for CDC RFA DP14 1404 Funding Number: CDC RFA DP14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Immunization and Vaccines for Children Program Apply for CDC RFA IP13 1301PPHF15 Funding Number: CDC RFA IP13 1301PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $33,000,000 |
| Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01) Apply for PA 14 218 Funding Number: PA 14 218 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Center for Integrative Medicine in Primary Care Program Apply for HRSA 14 123 Funding Number: HRSA 14 123 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| CONNECTING KIDS TO COVERAGE Outreach and Enrollment Grants Focused on Increasing Enrollment of American Indian/Alaska Native Children Apply for CMS 1Z0 14 001 Funding Number: CMS 1Z0 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $500,000 |
| NK Cells to Induce Immunological Memory to Prevent HIV Infection (R01) Apply for PA 14 217 Funding Number: PA 14 217 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| B Cell Help Immunology Program for AIDS Vaccine Strategies (R01) Apply for PA 14 216 Funding Number: PA 14 216 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R21) Apply for PA 14 214 Funding Number: PA 14 214 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| HIV Vaccine Vector Host Interactions Understanding the Biology and Immunology (R01) Apply for PA 14 215 Funding Number: PA 14 215 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Renewal Awards of SBIR Phase IIB Grants for Brain and Behavior Tools (R44) Apply for PA 14 219 Funding Number: PA 14 219 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Preventing Injuries and Violence by Informing State Strategies Apply for CDC RFA CE14 1403 Funding Number: CDC RFA CE14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01) Apply for PAR 14 220 Funding Number: PAR 14 220 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Confirmatory Efficacy Clinical Trials of Non Pharmacological Interventions for Mental Disorders (R01) Apply for RFA MH 15 340 Funding Number: RFA MH 15 340 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Local Nongovernmental Partnerships for Sustained Country Leadership in Zimbabwe under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1413 Funding Number: CDC RFA GH14 1413 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| FY14 Partnerships to Increase Coverage in Communities Initiative Apply for MP CPI 14 003 Funding Number: MP CPI 14 003 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Service Area Competition Additional Area (SAC AA) Cincinnati, Ohio Apply for HRSA 14 146 Funding Number: HRSA 14 146 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Limited Competition National Primate Research Centers (P51) Apply for PAR 14 226 Funding Number: PAR 14 226 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multiple Approaches to Increase Awareness and Support among Young Women Diagnosed with Breast Cancer Apply for CDC RFA DP14 1408 Funding Number: CDC RFA DP14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Evidence Based Tele Emergency Network Grant Program Apply for HRSA 14 138 Funding Number: HRSA 14 138 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIH Science Education Partnership Award (SEPA) (R25) Apply for PAR 14 228 Funding Number: PAR 14 228 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH14 1411", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.